# Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial

**Shadi Yaghi, MD**[1,2], **Adam de Havenon, MD**[3], **Sara Rostanski, MD**[1,2], **Alexandra Kvernland, MD**[1,2], **Brian Mac Grory, MD**[4], **Karen L. Furie, MD**[5], **Anthony S. Kim, MD**[6], **J. Donald Easton, MD**[6], **S. Claiborne Johnston, MD, PhD**[7], **Nils Henninger, MD, PhD, Dr med**[8,9]

[1]NYU Grossman School of Medicine, New York, NY

[2]Department of Neurology, NYU Langone Health, New York, NY

[3]Departments of Neurology, University of Utah Medical Center, Salt Lake City, UT

[4]Department of Neurology, Duke University, Durham, NC

[5]Department of Neurology, Brown University, Providence, RI

[6]Department of Neurology, University of California, San Francisco, CA

[7]Dean's Office, Dell Medical School, The University of Texas at Austin, TX

[8]Department of Neurology, University of Massachusetts Medical Center, Worcester, MA

[9]Department of Neurology, University of Massachusetts Medical Center, Worcester, MA

## Abstract

**Background and Purpose—**Randomized trials demonstrated the benefit of dual antiplatelet therapy in minor ischemic stroke or high-risk transient ischemic attack (TIA) patients. We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis.

**Methods—**This is a post-hoc analysis of the POINT trial that randomized patients with minor ischemic stroke or high-risk TIA within 12 hours from last known normal to receive either clopidogrel plus aspirin or aspirin alone. The primary predictor was the presence of 50% stenosis in either cervical internal carotid artery. The primary outcome was ischemic stroke. We built Cox regression models to determine the association between carotid stenosis and recurrent ischemic stroke and whether the effect of clopidogrel was modified by 50% carotid stenosis.

**Results—**Among 4881 patients enrolled POINT, 3941 patients met the inclusion criteria. In adjusted models, 50% carotid stenosis was associated with ischemic stroke risk (HR 2.45 95% CI 1.68-3.57, p<0.001). The effect of clopidogrel (versus placebo) on ischemic stroke risk was not

**Correspondence** Shadi Yaghi MD FAHA, Department of Neurology, New York University School of Medicine, 150 55th Street, Brooklyn, NY 11220, Phone: 718-630-7000 shadiyaghi@yahoo.com.

Author contribution:

Study design and drafting manuscript: Dr. Yaghi, Dr. de Havenon, and Dr. Henninger

Manuscript revision: Dr. Rostanski, Dr. Kvernland, Dr. Mac Grory, Dr. Furie, Dr. Kim, Dr. Easton, and Dr. Johnston.

**Supplementary Materials:** Online Supplementary Tables I and II, Online Supplementary Figures I and II.

significantly different in patients with <50% carotid stenosis (adjusted HR 0.68 95% CI 0.50-0.93, p=0.014) versus those with 50% carotid stenosis (adjusted HR 0.88 95% CI 0.45 – 1.72, p = 0.703), p-value for interaction = 0.573.

**Conclusion—**The presence of carotid stenosis was associated with increased risk of ischemic stroke during follow-up. The effect of added clopidogrel was not significantly different in patients with versus without carotid stenosis.

**Clinical Trial Registration Information—**https://clinicaltrials.gov/ct2/show/NCT00991029; ClinicalTrials.gov Identifier: NCT03354429

## Keywords

carotid stenosis; clopidogrel; stroke; recurrence

## Introduction

Randomized controlled trials showed benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy in reducing ischemic stroke risk in patients with minor ischemic stroke and high risk TIA.[1-3] Previous studies showed that carotid stenosis is associated with increased risk of recurrence in patients with TIA or minor ischemic stroke.[4] We sought to determine whether the presence of carotid stenosis was associated with ischemic stroke risk and whether addition of clopidogrel to aspirin was more beneficial in patients with versus without carotid stenosis.

## Methods

### Patient cohort

The New York Langone Health Institutional Review Board waived the need for formal review because this study used existing de-identified data. Data from this study is publicly available by the NIH upon reasonable request. This is a post-hoc analysis of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial that enrolled patients with minor stroke (NIHSS 3) and high-risk TIA ($ABCD^2$ score 4) within 12 hours from last known normal and randomized to receive either DAPT (aspirin and clopidogrel) or aspirin alone, followed for 90 days. In the present study, we included patients enrolled in the POINT trial who: (1) underwent at least one carotid imaging study, (2) had at least one day of follow-up and (3) did not undergo carotid endarterectomy.

### Primary predictor

The presence and degree of carotid stenosis were determined by participating sites based on the results of vascular imaging studies (carotid ultrasound, CT angiography [CTA], MR angiography [MRA], or conventional cerebral angiography). We dichotomized patients to <50% versus 50% stenosis in either cervical internal carotid artery. We allowed conventional angiography measurement to replace all other measurements and CTA or MRA measurements to replace carotid ultrasound. The infarct territory on brain imaging was determined by the site investigator. In a sensitivity analysis, we trichotomized the cohort to <50% stenosis, 50% stenosis with no infarct OR infarct that is not ipsilateral to the stenotic

carotid (asymptomatic stenosis), and 50% stenosis with an infarct ipsilateral to the stenotic carotid (symptomatic stenosis).

### Outcome

The outcome of interest was 90-day ischemic stroke using a tissue-based definition of stroke.

### Statistical analysis

We tested for intergroup differences with Student's t-test for continuous variables and chi-squared test for categorical variables. We fit Cox proportional hazards models to our outcome and report unadjusted hazard ratios and hazard ratios adjusted for patient age, sex, race, ethnicity, qualifying event (stroke vs. TIA), smoking status, diabetes, hypertension, coronary artery disease, and statin use. The proportional hazards assumption was tested and met for the adjusted Cox models by testing Schoenfeld residuals (p=0.2). To test our hypothesis that the effect of DAPT treatment differed by categories of carotid stenosis, we included stenosis*treatment arm (DAPT versus aspirin) interaction in the model with p<0.1 for a statistically significant interaction effect. Subsequently, we stratified Cox models by carotid stenosis and reported the hazard ratio for the DAPT arm in the stratifications. Kaplan-Meier failure curves were used to show events in the stratifications. Analyses were performed using Stata 16.1 (StataCorp, College Station, TX).

## Results

Among 4881 patients randomized in POINT, 3941 patients met the inclusion criteria (Supplemental Figure I, Supplemental Table I). Baseline characteristics and outcomes of patients with versus with <50% carotid stenosis are shown in Table 1. On unadjusted analysis, presence of 50% (versus <50%) carotid stenosis was associated with higher ischemic stroke rate during follow up (13.0% versus 4.9%, p <0.001). In sensitivity analysis, recurrent stroke rate was greater in patients with symptomatic versus asymptomatic stenosis (23.5% vs. 10.4%, p<0.001).

In adjusted models, when compared to patients with <50% carotid stenosis, ischemic stroke risk was increased in patients with 50% asymptomatic stenosis (adjusted HR 2.54, 95% CI 1.52-4.23, p<0.001) and symptomatic 50% carotid stenosis (adjusted HR 3.50, 95% CI 2.06-5.98, p<0.001), respectively (Supplementary Table II).

Recurrent ischemic stroke risk reduction by clopidogrel seemed more pronounced in patients without carotid stenosis (adjusted HR 0.68 95% CI 0.50-0.93, p=0.014) as opposed to those with carotid stenosis (adjusted HR 0.88 95% CI 0.45 – 1.72, p = 0.703), but the stenosis*treatment arm interaction was not significant (p = 0.573; Table 2; Figure 1).

We conducted additional analyses by trichotomizing the degree of carotid stenosis to 0% versus 1-49% versus 50%. Kaplan-Meier analysis indicated a similar risk of stroke recurrence for patients with 0% versus 1-49% stenosis (Supplemental Figure II).

## Discussion

Presence of a 50% carotid stenosis among patients with minor-ischemic stroke or high-risk TIA significantly increases the risk for recurrent ischemic stroke; this risk was highest for patients considered to have a symptomatic carotid stenosis. The effect of DAPT on recurrence was not significantly different in patients with or without arterial stenosis, in line with prior studies.[5, 6]

Patients with high-risk TIA or minor stroke and 50% carotid stenosis were at high risk for recurrence despite DAPT, indicating the importance of further secondary prevention strategies. In addition to carotid revascularization when deemed symptomatic, promising approaches include the use of anti-inflammatory drugs (colchicine), novel lipid lowering agents (evolocumab, alirocumab, and ezetimibe), and direct oral anticoagulants.

Strengths of our study relate to the use of data from a large multicenter randomized controlled trial. Limitations include its retrospective nature, modest number of patients with carotid stenosis, exclusion of patients in whom carotid revascularization was planned, as well as lack of data on ischemic stroke mechanism, intracranial stenosis, reasons why patients with symptomatic carotid stenosis were not considered for carotid revascularization, and potential misclassification of carotid artery stenosis as asymptomatic in patients with a TIA.

## Conclusion

Presence of carotid stenosis is associated with higher ischemic stroke risk but the effect of clopidogrel versus placebo is not significantly different in patients with versus without carotid stenosis. DAPT is recommended in patients with carotid stenosis who qualify when acute intervention is not anticipated. Further study is required to test the safety and efficacy of DAPT prior to planned carotid intervention.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

**Disclosures:**

Dr. Johnston reports research support from AstraZeneca as well as funding from Sanofi. Dr. de Havenon reports research support from AMAG and Regeneron. Dr. Kim reports funding from SanBio. Dr. Rostanski reports personal expert witness fees outside the submitted work. All other authors report no disclosures.

## Non-standard Abbreviations and Acronyms:

| | |
|---|---|
| **CI** | Confidence interval |
| **DAPT** | Dual antiplatelet therapy |
| **HR** | Hazard ratio |
| **POINT** | Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke |
| **TIA** | transient ischemic attack |

## References

1. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. The New England journal of medicine. 2013;369:11–19 [PubMed: 23803136]

2. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. The New England journal of medicine. 2018;379:215–225 [PubMed: 29766750]

3. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or tia. N Engl J Med. 2020;383:207–217 [PubMed: 32668111]

4. Yaghi S, Rostanski SK, Boehme AK, Martin-Schild S, Samai A, Silver B, Blum CA, Jayaraman MV, Siket MS, Khan M, et al. Imaging parameters and recurrent cerebrovascular events in patients with minor stroke or transient ischemic attack. JAMA Neurol. 2016;73:572–578 [PubMed: 26998948]

5. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke; a journal of cerebral circulation. 2020;51:3504–3513

6. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, Zou X, Pan Y, Wang A, Meng X, et al. Dual antiplatelet therapy in stroke and icas: Subgroup analysis of chance. Neurology. 2015;85:1154–1162 [PubMed: 26330567]

**Figure 1.**
Kaplan-Meier curves for ischemic stroke events within 90 days, shown stratified by stenosis <50% versus  50% and randomization arms.

**Table 1.**

Baseline demographics in patients with and without carotid stenosis ≥50%

| Variable | Full cohort (n=3,941) | Carotid stenosis <50% (n=3,665) | Carotid stenosis ≥50% (n=276) | p value[*] |
|---|---|---|---|---|
| Age | 64.6±13.0 | 64.1±13.0 | 70.3±11.1 | <0.001 |
| Male sex | 2,196 (55.7%) | 2,019 (55.1%) | 177 (64.1%) | 0.004 |
| Race | | | | |
|    White | 2,924 (74.2%) | 2,695 (73.5%) | 229 (83.0%) | |
|    Black | 739 (18.8%) | 697 (19.0%) | 42 (15.2%) | 0.001 |
|    Asian | 119 (3.0%) | 118 (3.2%) | 1 (0.4%) | |
|    Other | 159 (4.0%) | 155 (4.2%) | 4 (1.5%) | |
| Hispanic ethnicity | 278 (7.1%) | 266 (7.3%) | 12 (4.4%) | 0.069 |
| Final diagnosis of infarct (n=3,937) | 1,498 (38.1%) | 1,351 (36.9%) | 147 (53.3%) | <0.001 |
| Hypertension (n=3,925) | 2,708 (69.0%) | 2,481 (68.0%) | 227 (82.9%) | <0.001 |
| Diabetes (n=3,933) | 1,050 (26.7%) | 966 (26.4%) | 84 (30.4%) | 0.145 |
| Atrial fibrillation (n=3,931) | 37 (0.9%) | 34 (0.9%) | 3 (1.1%) | 0.790 |
| Coronary artery disease (n=3,932) | 397 (10.1%) | 343 (9.4%) | 54 (19.7%) | <0.001 |
| Congestive heart failure (n=3,937) | 99 (2.5%) | 90 (2.5%) | 9 (3.3%) | 0.412 |
| Statin at 7 days from randomization (n=3,911) | 3,107 (79.4%) | 2,860 (78.7%) | 247 (89.8%) | <0.001 |
| Smoking status | | | | |
|    Never | 2,055 (52.2%) | 1,942 (53.0%) | 113 (40.9%) | |
|    Past | 1,083 (27.5%) | 986 (26.9%) | 97 (35.1%) | <0.001 |
|    Current | 802 (20.3%) | 736 (20.1%) | 66 (23.9) | |
| NIH Stroke Scale at randomization (n=2,809) | 1, 0-2 | 1, 0-2 | 1, 0-2 | 0.430 |
| First measured systolic blood pressure (n=3,936) | 161.8±27.5 | 161.7±27.5 | 162.5±27.0 | 0.656 |
| First measured diastolic blood pressure (n=3,937) | 88.1±16.8 | 88.3±16.7 | 85.5±17.6 | 0.007 |
| Baseline glucose (n=3,941) | 130.2±60.4 | 129.8±65.8 | 135.0±67.3 | 0.169 |
| Clopidogrel treatment arm | 1,969 (50.0%) | 1,830 (49.9%) | 139 (50.4%) | 0.890 |
| Ischemic stroke during follow-up | 276 (7.0%) | 178 (4.9%) | 36 (13.0%) | <0.001 |

[*] Binary variables presented as n (%); ordinal variables as median, IQR; interval variables as mean±standard deviation. P values for difference between carotid stenosis groups, calculated with the chi-squared test for binary variables, the Wilcoxon rank sum test for ordinal variables, and Student's t-test for interval variables.

**Table 2.**

Event rates and Cox models showing hazard ratios for the clopidogreal treatment arm, stratified by carotid stenosis <50% versus   50%, and a model with the interaction term of stenosis*treatment.

| Stratification | Placebo event rate (n, %) | Clopidogrel event rate (n, %) | Unadjusted hazard ratio (95% CI) | p value | Adjusted hazard ratio[*] (95% CI) | p value |
|---|---|---|---|---|---|---|
| Stenosis <50% (n=3,665) | 105/1835, 5.7% | 73/1830, 4.0% | 0.69 (0.51-0.93) | 0.014 | 0.68 (0.50-0.93) | 0.014 |
| Stenosis   50% (n=276) | 19/137, 13.9% | 17/139, 12.2% | 0.86 (0.45-1.65) | 0.650 | 0.88 (0.45-1.72) | 0.703 |
| Interaction of stenosis*treatment | | | | | | 0.573 |

[*] Adjusted for age, sex, race, ethnicity, qualifying event (stroke vs transient ischemic attack), smoking status, diabetes, hypertension, coronary artery disease, and statin use.